15,524 Shares in Prestige Consumer Healthcare Inc. (NYSE:PBH) Acquired by DAVENPORT & Co LLC

DAVENPORT & Co LLC purchased a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 15,524 shares of the company’s stock, valued at approximately $1,212,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC lifted its position in Prestige Consumer Healthcare by 19.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock worth $113,570,000 after acquiring an additional 255,045 shares during the period. Geode Capital Management LLC raised its stake in shares of Prestige Consumer Healthcare by 4.0% during the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after purchasing an additional 50,961 shares during the last quarter. Congress Asset Management Co. lifted its holdings in shares of Prestige Consumer Healthcare by 7.8% during the third quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock worth $62,375,000 after purchasing an additional 62,411 shares during the period. Boston Trust Walden Corp acquired a new stake in shares of Prestige Consumer Healthcare during the third quarter worth $41,785,000. Finally, Eagle Asset Management Inc. grew its position in Prestige Consumer Healthcare by 0.7% in the 3rd quarter. Eagle Asset Management Inc. now owns 434,514 shares of the company’s stock valued at $31,328,000 after buying an additional 3,227 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, insider William P’pool sold 8,987 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the transaction, the insider now directly owns 20,058 shares in the company, valued at $1,641,747.30. This represents a 30.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,810 shares of company stock valued at $3,187,300. 1.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

PBH has been the subject of several analyst reports. StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. DA Davidson reissued a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a report on Monday, December 9th. Finally, Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $85.25.

Prestige Consumer Healthcare Stock Performance

NYSE PBH opened at $87.21 on Friday. The business’s 50-day simple moving average is $79.13 and its 200-day simple moving average is $75.26. The firm has a market capitalization of $4.31 billion, a P/E ratio of 21.22, a P/E/G ratio of 2.15 and a beta of 0.50. Prestige Consumer Healthcare Inc. has a 1-year low of $60.00 and a 1-year high of $87.39. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. Equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.46 EPS for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.